The dipeptide boronic acid analogue VELCADE (Bortezomib; formerly known as PS-341, LDP-341 and MLM341) is a potent and selective inhibitor of the proteasome, a multicatalytic enzyme that mediates many cellular regulatory signals by degrading regulatory proteins or their inhibitors. The proteasome is, thus, a potential target for pharmacological agents. Bortezomib, the first proteasome inhibitor to…
Cancer Investigation Template
Write in a clean editor, then format for Cancer Investigation in one click — DocuGuru applies the official Taylor & Francis template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Cancer Investigation format
Cancer Investigation is a peer-reviewed journal published by Taylor & Francis, covering Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies.
| Publisher | Taylor & Francis |
|---|---|
| Reference style | Author–year (Chicago, T&F) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Cancer Investigation 12 (3): 45–58.
Formats any DOI in Cancer Investigation style. No sign-up. |
| Publishes research in | Cancer Treatment and Pharmacology Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies Lymphoma Diagnosis and Treatment Breast Cancer Treatment Studies |
| ISSN | 0735-7907 |
| Citation impact (2-yr) | 1.78 |
| h-index | 114 |
| i10-index | 2,053 |
| Total citations | 87,799 |
| Top institutions publishing here | Memorial Sloan Kettering Cancer Center |
| Journal website | informahealthcare.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Cancer Investigation per year
Citation impact of Cancer Investigation by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Cancer Investigation
Pegylated liposomal doxorubicin (Doxil, Caelyx) is a formulation of doxorubicin in poly(ethylene glycol)-coated (stealth) liposomes with a prolonged circulation time and unique toxicity profile. We review the preclinical and clinical pharmacology as well as recent clinical data obtained in specific cancer types. Doxil liposomes retain the drug payload during circulation and accumulate preferentially in tissues…
Spontaneous tumors in companion animals (dog and cat) offer a unique opportunity as models for human cancer biology and translational cancer therapeutics. The relatively high incidence of some cancers, similar biologic behavior, large body size, comparable responses to cytotoxic agents, and shorter overall lifespan are the factors that contribute to the advantages of the companion…
CEA is a complex glycoprotein produced by 90% of colorectal cancers and contributes to the malignant characteristics of a tumor. It can be measured in serum quantitatively, and its level in plasma can be useful as a marker of disease. Because of its lack of sensitivity in the early stages of colorectal cancer, CEA measurement…
PURPOSE: Severe treatment-related lymphopenia (TRL) occurs in 40% of patients with high grade gliomas (HGG) receiving glucocorticoids, temozolomide, and radiation. This occurs following radiation, persists for months, and is associated with reduced survival. As all three treatment modalities are lymphotoxic, this study was conducted to estimate the radiation dose that lymphocytes receive passing through the…